Abinopharm and EGT Synbio Announce Successful Clinical Trials
Abinopharm, Inc., a pioneering nutritional and biopharmaceutical firm located in Shelton, Connecticut, has reported significant progress in collaboration with its partner, EGT Synbio from Shanghai, China. The two organizations have successfully completed two human clinical trials assessing the impact of oral L-ergothioneine (Dr.Ergo®) on skin health. Abinopharm is the exclusive distributor and collaborator in the United States for EGT Synbio’s premium product, Dr.Ergo®.
Understanding L-Ergothioneine
L-Ergothioneine, first discovered in 1909 by French chemist Charles Tanret from the ergot fungus (Claviceps purpurea), combines its name from “ergo,” referring to ergot, and “thioneine,” indicating a sulfur-rich compound. Although ergothioneine is present in various plants and animals, it cannot be produced by them and must be obtained from fungi, particularly mushrooms, along with certain bacteria. Humans primarily derive ergothioneine from consuming mushrooms such as shiitake, maitake, and oyster, which contain between 10-13 mg per 100 grams of dry weight.
For many years, the significance of ergothioneine in biological processes was largely unknown until 2005, when Professor Günther Gündemann identified the ergothioneine-specific transporter OCTN1 (SLC22A4), crucial for its accumulation in nearly all human tissues, most notably in the bone marrow, liver, kidneys, red blood cells, brain, eyes, and skin. Leading researcher Professor Barry Halliwell later recognized ergothioneine as one of the most effective natural antioxidants, illustrating its role in reducing oxidative damage and inflammation—key contributors to diseases such as Alzheimer’s, Parkinson’s, cardiovascular issues, and liver conditions. Research has indicated that ergothioneine possesses high bioavailability, a prolonged half-life in the human body, and offers cellular protection, particularly within mitochondria, which aids in cognitive function, reduces inflammation, and promotes healthy aging.
In 2018, esteemed biochemist Professor Bruce Ames suggested that ergothioneine should be regarded as a “longevity vitamin,” highlighting its importance for long-term health and aging, even though it is not essential for immediate survival. He indicated that insufficient levels of ergothioneine could accelerate aging and elevate the likelihood of chronic diseases.
Benefits of Ergothioneine for Skin Health
Ergothioneine is recognized as a versatile skincare nutrient, celebrated for its antioxidant capabilities, anti-inflammatory properties, and protection against UV damage. It shields skin cell components—including lipids, DNA, and proteins—from oxidative harm and premature aging. Additionally, it helps combat photoaging, characterized by sunspots and collagen degradation, alleviates redness and inflammation related to conditions like acne and eczema, promotes an even skin tone and radiance, bolsters collagen production and skin elasticity, and enhances hydration.
Recent Clinical Findings on Dr.Ergo®
Abinopharm and EGT Synbio have announced the findings from two human clinical trials assessing the skin health benefits of Dr.Ergo® L-ergothioneine. The first trial, an open-label study conducted in China in 2023, involved 19 healthy participants who ingested 25 mg of Dr.Ergo® daily for four weeks. Dermatological evaluations utilizing the VISIA imaging system indicated noticeable improvements in skin pores, wrinkles, UV spots, brown spots, and porphyrins, with no reported adverse effects. These results were published in the American Journal of Biomedical Science & Research.
The second trial, a double-blind, placebo-controlled study in Japan carried out in 2024, included 66 healthy women aged between 35 and 59. Participants were administered 30 mg of Dr.Ergo® daily for eight weeks. Scientific assessments and questionnaires revealed statistically significant enhancements in skin brightness, tone, melanin levels, erythema, gloss, elasticity, and wrinkles. No considerable adverse events were noted, and further details can be found on ClinicalTrials.gov.
Commitment to Quality and Safety
Dr.Ergo® is manufactured using a patented full enzymatic fermentation process under stringent cGMP standards. It has received the U.S. FDA’s Generally Recognized as Safe (GRAS) status, along with NSF GMP certification, HACCP compliance, and HALAL certification. The product meets ICH quality guidelines, ensuring a purity and optical purity exceeding 99.9%. All impurities, heavy metals, and microbial levels are maintained within USP limits, reinforcing the commitment to quality and safety.
About EGT Synbio
EGT Synbio is at the forefront of developing biological solutions aimed at anti-aging. Their scientific team focuses on creating clinically validated compounds, including the premium Dr.Ergo® L-Ergothioneine, which is an odorless and stable crystal ingredient utilized by global brands and recognized by U.S. GRAS, EU Novel Food, and NSF certifications. In 2024, EGT Synbio expanded its product line with EquoPro™ (S)-Equol and Dr.SPD™ Spermidine Hydrochloride, introducing new offerings in dietary supplements, skincare, and pharmaceuticals, now widely adopted in functional foods, luxury beauty, and medical-grade nutrition.
About Abinopharm, Inc.
Abinopharm, Inc. is a U.S.-based nutritional and biopharmaceutical company dedicated to developing, manufacturing, and commercializing high-quality health products both domestically and internationally. The nutritional division focuses on longevity-related ingredients, collaborating with prominent academic and industry leaders. The company’s NMN ingredient (AbinoNutra®NMN) has been self-affirmed as GRAS and validated through partnerships with experts such as Professor Andrea Maier. Other notable ingredients include L-Ergothioneine (Dr.Ergo®), Fisetin (BeFisetin®), Urolithin A, CaAKG, Spermidine (Dr.SPD™), S-Equol (EquoPro™), and Hydroxytyrosol. Abinopharm also provides regulatory support and private-label solutions for supplements manufactured in the U.S., Canada, and Europe.
